• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Allied Minds launches Novare Pharmaceuticals

Allied Minds launches Novare Pharmaceuticals

October 8, 2014
CenterWatch Staff

Allied Minds, a Boston, Mass.-based science and technology development and commercialization company, has launched Novare Pharmaceuticals, a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue through the modulation of Receptor for Hyaluronan Mediated Motility (RHAMM). Modulation of RHAMM also is of benefit in inflammatory diseases such as bronchopulmonary dysplasia (BPD).

Novare is an expansion of the Allied Minds subsidiary previously called ProGDerm, which is developing a dermal filler for aesthetic applications that works via the modulation of the RHAMM. This research is being led by Dr. Eva Turley, an oncology scientist at the London Health Sciences Center (LHSC) in London, Ontario, in collaboration with MJ Bissell, a cell biologist at Lawrence Berkeley National Laboratories in Berkeley, Calif. Turley and colleagues now have uncovered the potential for additional applications of RHAMM modulation that may help solve medical challenges including arthritis, fibrotic diseases such as BPD in premature infants and idiopathic pulmonary fibrosis and the reduction and possible elimination of keloid scars.

This breakthrough in tissue engineering also may provide an opportunity to regenerate and reconstruct women's breasts after a mastectomy through the localized stimulation of the body's own adipocyte (fat) stem cells. Novare has licensed from LHSC additional RHAMM compounds discovered by Turley, who also is Novare's chief scientist, and Dr. Leonard Luyt, a peptide chemist at LHSC, allowing the company to more than double its library of RHAMM-binding peptides—and increase potential applications.

RHAMM is a protein that is normally localized inside the cell but is released by certain stimuli. It plays a role in the regulation of spontaneous cell movement and stem cell differentiation. Turley and colleagues found that modulating RHAMM provides the safest and most efficacious means to selectively promote subcutaneous fat generation (adipogenesis), moderate destructive inflammation and reduce scarring (fibrosis) by stimulating normal cell differentiation and controlling the body's own natural regenerative processes.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing